Diabetes, Diabetes Mellitus, Type 2, Healthy
Conditions
Brief summary
This trial is conducted in Europe. The aim of the trial is to investigate safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) of single doses of NNC0113-0987 in healthy male subjects.
Interventions
DRUGNNC0113-0987
A single dose for oral administration, up to 7 dose levels will be investigated. If a non-tolerated dose level has been reached, the dose level will not be increased further.
DRUGplacebo
A single dose of oral placebo administered.
Sponsors
Novo Nordisk A/S
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Male subjects with good general health as judged by the investigator, based on medical history, physical examination including 12-lead electrocardiogram (ECG), vital signs, and blood assessments at the screening visit * Body mass index (BMI) above or equal to 18.5 and below 30 kg/m\^ 2
Exclusion criteria
* Male subjects who are sexually active and not surgically sterilised, who or whose partner is unwilling to use two different forms of effective contraception, one of which has to be a barrier method (e.g., condom with spermicidal foam/gel/film/cream) for the duration of the trial and for 12 weeks following the last dose of trial medication * Participation in another trial within 90 days prior to screening * Subjects with a history of or presence of cancer, diabetes, or any clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal (including gastroesophageal reflux disease and irritable bowel syndrome), endocrinological, haematological, dermatological, venereal, neurological, or psychiatric disease or other major disorders that might have an impact on the current trial, as judged by the investigator * Subjects who are known to have hepatitis or who are carriers of the Hepatitis B surface antigen (HBsAg) or Hepatitis C antibodies, or have a positive result to the test for Human Immunodeficiency Virus (HIV) antibodies * History of acute idiopathic or chronic pancreatitis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of treatment emergent adverse events (TEAEs) | From the dosing visit and until completion of the post-treatment follow-up visit (i.e. day 12-25) |
Secondary
| Measure | Time frame |
|---|---|
| Number and severity of hypoglycaemic episodes | From dosing visit and until completion of the post-treatment follow-up visit (i.e. day 12-25) |
| AUC, the area under the NNC0113-0987 plasma concentration-time curve | From dosing visit to infinity |
| Cmax, the maximum plasma concentration of NNC0113-0987 | From dosing visit until last PK sampling visit (e.g. day 11) |
| tmax, the time to maximum plasma concentration of NNC0113-0987 | From dosing visit until last PK sampling visit (e.g. day 11) |
Countries
United Kingdom
Outcome results
None listed